HIV-1 Integrase-DNA Recognition Mechanisms.

Viruses

Center for Retrovirus Research and Comprehensive Cancer Center, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA; E-Mails: (J.J.K.); (C.J.M.); (J.O.E.), (N.S.); (A.K.).

Published: December 2009

Integration of a reverse transcribed DNA copy of the HIV viral genome into the host chromosome is essential for virus replication. This process is catalyzed by the virally encoded protein integrase. The catalytic activities, which involve DNA cutting and joining steps, have been recapitulated in vitro using recombinant integrase and synthetic DNA substrates. Biochemical and biophysical studies of these model reactions have been pivotal in advancing our understanding of mechanistic details for how IN interacts with viral and target DNAs, and are the focus of the present review.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185514PMC
http://dx.doi.org/10.3390/v1030713DOI Listing

Publication Analysis

Top Keywords

hiv-1 integrase-dna
4
integrase-dna recognition
4
recognition mechanisms
4
mechanisms integration
4
integration reverse
4
reverse transcribed
4
transcribed dna
4
dna copy
4
copy hiv
4
hiv viral
4

Similar Publications

Article Synopsis
  • At week 48 of the DAWNING study, dolutegravir plus two nucleoside reverse transcriptase inhibitors showed better virologic suppression than ritonavir-boosted lopinavir in adults with HIV-1 who had previously failed treatment.
  • Among the 314 participants, 7 developed treatment-emergent INSTI resistance-associated mutations, indicating some resistance to dolutegravir, though they still achieved low HIV-1 RNA levels.
  • The study reveals that while mutations can confer some resistance to dolutegravir, this resistance comes with a significant trade-off: a decrease in the virus’s ability to replicate effectively.
View Article and Find Full Text PDF

The HIV integrase (IN) strand transfer inhibitor (INSTI) bictegravir (BIC) has a long dissociation half-life (t) from wild-type IN-DNA complexes: BIC 163 hr > dolutegravir (DTG) 96 hr > raltegravir (RAL) 10 hr > elvitegravir (EVG) 3.3 hr. In cells, BIC had more durable antiviral activity against wild-type HIV after drug washout than RAL or EVG.

View Article and Find Full Text PDF

: The oligomerization of HIV-1 integrase onto DNA is not well understood. Here we show that HIV-1 integrase binds the DNA in biphasic (high-affinity and low-affinity) modes. For HIV-1 subtype B, the high-affinity mode is ∼100-fold greater than the low-affinity mode (Kd.

View Article and Find Full Text PDF

Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence.

Sci Rep

October 2017

Laboratory of Biology and Applied Pharmacology (LBPA), CNRS UMR8113, IDA FR3242, ENS Paris-Saclay, Université Paris-Saclay, F-94235, Cachan, France.

FDA-approved integrase strand transfer inhibitors (raltegravir, elvitegravir and dolutegravir) efficiently inhibit HIV-1 replication. Here, we present fluorescence properties of these inhibitors. Dolutegravir displays an excitation mode particularly dependent on Mg chelation, allowing to directly probe its Mg-dependent binding to the prototype foamy virus (PFV) integrase.

View Article and Find Full Text PDF

Crystal structure of the Rous sarcoma virus intasome.

Nature

February 2016

Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455, USA.

Integration of the reverse-transcribed viral DNA into the host genome is an essential step in the life cycle of retroviruses. Retrovirus integrase catalyses insertions of both ends of the linear viral DNA into a host chromosome. Integrase from HIV-1 and closely related retroviruses share the three-domain organization, consisting of a catalytic core domain flanked by amino- and carboxy-terminal domains essential for the concerted integration reaction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!